Explorez tous les épisodes du podcast EHA Unplugged
| Titre | Date | Durée | |
|---|---|---|---|
| How Experts Treat Chronic Lymphocytic Leukemia (CLL) | 16 oct. 2026 | 00:14:39 | |
Explore the latest EHA guidelines on chronic lymphocytic leukemia (CLL) and Richter transformation with key guideline authors Prof Barbara Eichhorst, hematologist at University Hospital Cologne (Germany), and Prof Paolo Ghia, Director of the CLL Program at Università Vita-Salute San Raffaele (Milan, Italy). For the first time, the guidelines no longer recommend chemoimmunotherapy when targeted options are available, based on two key advances: the approval of acalabrutinib plus venetoclax with or without obinutuzumab for frontline CLL, and the approval of pirtobrutinib, a non-covalent BTK inhibitor, for relapsed/refractory disease—particularly after prior covalent BTK inhibitor treatment. The guests also make clear that patient selection matters, including TP53 status, IGHV status, comorbidities, co-medications, safety profile, and patient preferences. Further, the experts highlight a landmark change in how the recommendations were developed: for the first time, patients and patient advocates participated as authors, bringing a patient-centred perspective to treatment decisions, active surveillance, and supportive care. Tune in for practical insights into personalized CLL management, fixed-duration targeted therapy, treatment sequencing, and the challenges of Richter transformation. Guests: Prof Barbara Eichhorst University of Cologne, Cologne, Germany Prof Paolo Ghia Università Vita-Salute San Raffaele, Milano, Italy Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How Experts Treat Hodgkin Lymphoma | 09 oct. 2026 | 00:12:19 | |
Stay up to date with the latest EHA guidelines on Hodgkin lymphoma. In this episode of EHA Unplugged, key guideline authors Prof. Dennis Eichenauer and Prof. Igor Aurer discuss the evidence reshaping the management of classic Hodgkin lymphoma. The discussion highlights the guideline’s central shift: the integration of targeted therapies—brentuximab vedotin and PD-1 inhibitors such as nivolumab—into frontline treatment. The experts explain updated approaches to staging and risk assessment, PET-guided treatment in early-stage disease, BrECADD for younger patients with advanced disease, and nivolumab–AVD for older patients, alongside recommendations for relapsed or refractory disease and autologous stem cell transplantation. They also consider survivorship, late effects, and the realistic prospects for chemotherapy-free, immune-based approaches. Tune in for practical, evidence-based insights into improving outcomes while reducing long-term toxicity in Hodgkin lymphoma. Guests: Prof. Dennis Eichenauer: University of Cologne, Germany; First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group, University of Cologne, Cologne, Germany Prof. Igor Aurer: University Hospital Centre Zagreb, and Medical School, University of Zagreb, Zagreb, Croatia Host: Nabil Dorkhom, MD / EHA Head of Education Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How to Improve Equity and Inclusion in Hematology: EHA2026 Diversity, Equity and Inclusion Award | 02 oct. 2026 | 00:14:55 | |
In this episode, Prof Gianluca Gaidano, recipient of the EHA2026 Diversity, Equity and Inclusion Award, explores how promoting equity, inclusion, and access to care has shaped his work within EHA and beyond. He reflects on educational initiatives in underrepresented regions, including Africa, the Middle East, Asia, and South America, and explains how international collaborations can help expand access to medical knowledge, advanced diagnostics, and innovative therapies. The discussion explores the difference between drug availability and true patient access, the role of education and patient advocacy in reducing disparities, and how partnerships with local hematology communities can strengthen clinical practice. Prof Gaidano also shares examples from countries such as Bangladesh, Iraq, and Albania, highlighting progress in access to diagnostics, treatments, and specialist training. Listen now for insights into how to contribute to building a more equitable future for hematology. Guest: Prof Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara, Italy Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Advancing Adult ALL Care in Europe: EHA2026 Clinical Excellence Award | 25 sept. 2026 | 00:20:41 | |
In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have transformed patient outcomes. He discusses the evolution of treatment for Philadelphia chromosome-positive ALL, from poor survival rates to highly effective targeted and immunotherapy-based approaches, and explains how tyrosine kinase inhibitors, blinatumomab, and chemotherapy-sparing strategies are reshaping care.
The discussion also explores the growing role of measurable residual disease (MRD) monitoring and genetic risk stratification in treatment decision-making, including identifying which patients can safely avoid allogeneic stem cell transplantation. Professor Ribera highlights the impact of collaborative research through PETHEMA, EWALL, and EHA, and shares his perspective on the future of hematology. Listen now for insights into the progress of ALL treatment and a message of optimism for patients and clinicians alike. Guest: Prof Josep-María Ribera Josep Carreras Leukemia Research Institute (IJC) and Universitat Autònoma de Barcelona, Spain Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Refining Transplantation and Cellular Therapy: Insights from 2026 Young EHA Award Winner Nico Gagelmann | 22 sept. 2026 | 00:22:45 | |
In this episode, Dr Nico Gagelmann, recipient of the 2026 Young EHA Award, discusses his career in stem cell transplantation and the values that have shaped his work. He explains how multidisciplinary care, patient selection, graft-versus-host disease prevention, and conditioning strategies can help improve transplant outcomes. The discussion also explores the role of real-world evidence in identifying best practices and supporting efforts to harmonize transplantation approaches across centres. Dr Gagelmann also highlights the evolving role of CAR T-cell therapy, ongoing disparities in access to innovative treatments, and the importance of collaboration, education, and knowledge sharing across countries. He reflects on building international professional communities, addressing inequalities in hematology care, and ensuring that future advances remain accessible to patients. Listen now for insights into the future of transplantation, cellular therapies, and global hematology collaboration. Guest: Dr Nico Gagelmann, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, and University Medical Center Hamburg-Eppendorf, Germany Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| What Can We Learn About AML from Clonal Haematopoiesis? | EHA 2026 Research Excellence Award | 18 sept. 2026 | 00:21:31 | |
In this episode, Prof George Vassiliou, recipient of the 2026 EHA Research Excellence Award, discusses how his research has advanced our understanding of clonal haematopoiesis and its relationship to acute myeloid leukaemia (AML). He explains how blood stem cells evolve over time, why specific driver mutations promote clonal expansion, and how genetic profiles can help identify individuals at low, intermediate, or high risk of developing myeloid malignancies. The discussion also explores efforts to translate these discoveries into clinical prevention strategies. Prof Vassiliou highlights emerging risk prediction models, the development of clinics focused on clonal haematopoiesis, and ongoing work to evaluate low-toxicity interventions that could reduce disease progression. He also examines the links between clonal haematopoiesis, cardiovascular disease, immune ageing, and age-related health outcomes, offering insights into the future of early detection and preventive approaches in haematology. Listen now for perspectives on how understanding clonal haematopoiesis may help reshape the prevention of AML and other age-related diseases. Guest: Prof George Vassiliou, Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Improving MPNs management: EHA2026 Lifetime Achievement Award | 15 sept. 2026 | 00:21:10 | |
In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She reviews the major scientific and clinical developments she has witnessed over more than two decades, including the discovery of JAK2, MPL and CALR mutations, the evolution of diagnostic criteria, and the emergence of targeted therapies for MPNs. The discussion explores landmark studies that helped shape current clinical practice, including PT-1, COMFORT-II and MAJIC-PV, as well as the growing role of patient advocacy in driving research and improving care. Prof Harrison also looks ahead to the next generation of therapies, including CALR-targeted immune approaches and combination treatment strategies, while highlighting the challenges and opportunities that remain for patients with MPNs. Listen now for insights from one of the leading figures in the field. Guest: Prof Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| CAR T Toxicities in Focus: What We Have Learned from Registry Data | 09 sept. 2026 | 00:17:44 | |
In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have helped improve early toxicities such as cytokine release syndrome (CRS) and ICANS awareness and management as well as helped recognise and address longer-term effects. She further explores the growing understanding of immune effector cell-associated hematotoxicity (ICAHT) and the importance of risk prediction and early intervention. Dr Ruggeri also discusses emerging safety questions as CAR T use expands, including secondary malignancies, long-term immune effects, and fertility outcomes. She highlights encouraging registry findings showing that fertility recovery and successful pregnancies are possible after CAR T therapy, offering renewed hope for patients seeking to return to normal life following treatment. Listen now for valuable insights into how registries, collaboration and long-term follow-up are helping improve cellular therapy. Guest: Dr Annalisa Ruggeri Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy Chair of the Cellular Therapy and Immunobiology Working Party (Education Portfolio), EBMT Host: Leah DeLeon Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Life After YERM: How the Young EHA Research Meeting Shaped Careers | 06 sept. 2026 | 00:21:05 | |
In the final episode of our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM), we explore how the meeting acts as a powerful launching pad for scientific careers. We talk to 2018 YERM speakers Dr. Lorena Arranz and Dr. Mattias Carlsten to hear about their experiences presenting their research at YERM. Looking back on their journeys, they share valuable advice and lessons learned at YERM to help guide today's early-career researchers. Dr Mattias Carlsten, Karolinska Institutet and Karolinska University Hospital, Sweden Dr. Lorena Arranz, University of Oslo and Oslo University Hospital, Oslo, Norway Host: Rhiannon Newman, MSc, University of Helsinki and Young EHA committee
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Discover YERM: The Young EHA Research Meeting and Your Place in It | 06 sept. 2026 | 00:19:28 | |
Welcome to our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM) with an introduction to its history and mission. We sit down with co-founder Prof Ruud Delwel and current organizer Prof Marlies Vanden Bempt to discuss how YERM is tailored to empower early-career researchers. Together, we reflect on a decade of growth and share their vision for the future of YERM. Guests: Prof Ruud Delwel, Erasmus Medical Centre, The Netherlands Prof Marlies Vanden Bempt, KU Leuven, Belgium Host: Rhiannon Newman, MSc, University of Helsinki and Young EHA committee Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| CAR-T for Pediatric B-ALL: Expert Tips | 28 août 2026 | 00:21:34 | |
In this episode, Prof André Baruchel discusses the role of CAR T-cell therapy in children with B-cell acute lymphoblastic leukemia (B-ALL). He reviews current indications for CAR T-cell treatment, including relapsed and refractory disease, and explores whether CAR T could move earlier in the treatment pathway. The discussion also examines how CAR T-cell therapy compares with transplantation, blinatumomab, and other salvage strategies, as well as the factors that influence long-term outcomes and relapse risk. The conversation highlights key questions surrounding the role of allo-HSCT in the CAR T era. Prof Baruchel also explores emerging approaches designed to improve outcomes, including dual-targeted CARs, strategies to enhance cellular persistence. Listen now for insights into how fourth-generation CAR constructs that modify the tumour microenvironment, and in vivo CAR therapies may further transform the treatment of pediatric B-ALL. Guests: Prof André Baruchel Affiliation: Professor of Pediatrics, Université Paris-Cité; former Head of the Pediatric Hematology Immunology Department, Hôpital Robert-Debré, Paris Host: Leah DeLeon Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Getting Patients to CAR T: Referral Systems in Europe | 25 août 2026 | 00:21:12 | |
In this episode of EHA Unplugged, Prof Marion Subklewe discusses one major challenge facing CAR T-cell therapy in Europe: ensuring that eligible patients are referred for treatment. She explains how access has improved since the first CAR T-cell approvals, but highlights that many eligible patients still do not receive these potentially curative therapies. The discussion explores differences between European healthcare systems, barriers to referral, and persistent misconceptions about patient eligibility. Prof Subklewe advocates for structured referral pathways and multidisciplinary boards that assess all eligible patients in collaboration with CAR T-cell experts. She argues that treatment eligibility should not depend solely on individual physicians and highlights the benefits of coordinated networks, shared decision-making, professional education, and patient engagement. Listen now for insights into how stronger referral systems could help more patients access CAR T-cell therapy across Europe. This podcast episode is supported by Bristol Myers Squibb. Guests: Prof Marion Subklewe Affiliation: LMU – University Hospital, LMU Munich Department of Hematology/Oncology LMU- Gene Center Munich Laboratory of Translational Cancer Immunology Germany Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Outpatient CAR T in Europe: Lessons from Barcelona | 21 août 2026 | 00:21:21 | |
In this episode, Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz discuss how their team at Hospital Clínic de Barcelona has developed a fully outpatient programme for CAR T-cell therapy. They explain the evolution of their at-home programme, from outpatient transplantation and supportive care to outpatient CAR T administration, and describe the key clinical and logistical requirements for patient selection. The discussion explores caregiver training, monitoring for cytokine release syndrome and neurotoxicity, and the importance of dedicated multidisciplinary teams. The guests also share their experience with outpatient CAR T across academic and commercial products, highlighting safety outcomes, early discharge strategies, resource utilisation, and patient-centred benefits. They discuss practical considerations for centres interested in establishing similar programmes, including infrastructure, staffing, legislation, and continuous evaluation. Listen now for insights into the opportunities and challenges of delivering CAR T therapy beyond the hospital ward. This podcast episode is supported by Bristol Myers Squibb. Guests: Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz Affiliation: Hospital Clínic de Barcelona, Spain Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Smarter CARs: Using AI to Improve Chimeric Antigen Receptor Design | 18 août 2026 | 00:17:42 | |
Artificial intelligence is opening new possibilities in the design of next-generation immunotherapies. In this episode of EHA Unplugged, Dr Andrea Schmidts discusses how AI-driven approaches are reshaping the development of chimeric antigen receptor (CAR) T-cell therapies, particularly at the design stage of the CAR receptor binding domains. Dr Schmidts explains how structure-based AI models can generate entirely new protein binders, moving beyond the traditional reliance on monoclonal antibody–derived fragments. The conversation explores how these tools enable large-scale exploration of CAR designs, the experimental challenges of validating thousands of candidates, and the potential to tailor therapies that overcome resistance mechanisms such as antigen escape. Looking ahead, Dr. Schmidts highlights the role of AI across the entire CAR T-cell development pipeline—from early design to testing and manufacturing—and reflects on the practical and regulatory considerations of bringing AI-designed therapies to the clinic. Guest: Dr Andrea Schmidts Affiliation: Emmy Noether Group Leader, Medicine III – Hematology/Oncology, Technical University of Munich, Germany Host: Leah de Leon Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| What is Real-World Evidence Revealing About CAR T Therapy? | 17 août 2026 | 00:18:39 | |
In this episode, Prof Benoit Tessoulin examines how real-world evidence from the French DESCAR-T registry is expanding our understanding of CAR T-cell therapy beyond clinical trials. He explains how the registry captures data from patients considered for CAR T-cell treatment, including those who do not ultimately receive therapy, and explores what these data reveal about patient selection, treatment outcomes, bridging therapy, and comparisons between different CAR T-cell products. The discussion also examines how real-world populations differ from clinical trial cohorts, in what measure registry data have confirmed the effectiveness of CAR T-cell therapy in routine practice, and what has been learned about toxicities such as CRS, ICANS, and infections. Prof Tessoulin highlights the importance of timely referral, evolving product selection strategies, and the growing role of patient registries in informing clinical decision-making and future research. Listen now for insights into how real-world data are informing CAR T-cell therapy updates. This podcast episode is supported by Bristol Myers Squibb. Guest: Prof Benoit Tessoulin Affiliation: Hematology Department, Centre Hospitalier Universitaire Nantes, France Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Hematology Portraits: Prof Frank Leebeek | 31 juil. 2026 | 00:22:40 | |
In this episode Prof. Frank Leebeek reflects on his career in hematology, highlighting a lifelong commitment to bridging clinical practice and research. From his early interest in fibrinolysis during medical school to his current role as Chair of the Department of Hematology at Erasmus Medical Center and Board member at EHA, Prof. Leebeek shares how a dual commitment to research and patient care has shaped his path. The conversation explores key milestones in bleeding disorders research, including large-scale studies on von Willebrand disease that helped improve awareness, diagnosis, and patient-reported outcomes. Prof. Leebeek also discusses his involvement in pioneering gene therapy trials for hemophilia, which have transformed treatment paradigms and patients’ quality of life, while noting ongoing challenges in access and affordability. Beyond research, he reflects on the importance of collaboration, the value of long-term patient relationships, and the role of European-level initiatives in advancing hematology care. Tune in to hear insights from a leading figure in benign hematology and learn how sustained collaboration and innovation continue to drive progress in the field. Guest: Prof Frank Leebeek Affiliation: Erasmus Medical Center, Rotterdam, The Netherlands Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How to Start a Clinical Trial? | 16 juil. 2026 | 00:18:46 | |
What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged, Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal investigator, and how the EHA Clinical Research Training in Hematology (CRTH) program helped shape his path. Prof. Mai reflects on the practical and often underappreciated challenges of clinical trial design—from budgeting and statistical planning to ethical considerations and regulatory requirements. He highlights the importance of mentorship and peer networks, as well as the need for persistence when ideas are ahead of their time. The conversation also explores the skills hematologists need to get started in clinical research, with a clear message: developing trials is a multifaceted process that requires both scientific expertise and hands-on learning. Whether you are early in your career or considering a move into clinical research, this episode offers valuable insights into how to take the first steps, overcome challenges, and ultimately contribute to improving patient care through clinical trials. Guests: Prof Elias K. Mai Heidelberg University Hospital, Heidelberg, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How Experts Treat Multiple Myeloma | 03 juil. 2026 | 00:35:39 | |
In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma. The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibody-drug conjugates—have reshaped the treatment landscape and informed the latest recommendations. The experts discuss the integration of novel prognostic tools such as minimal residual disease (MRD), circulating tumour cells and mass spectrometry, and their evolving role in risk stratification. The episode also reviews key recommendations for frontline management and provides practical guidance for selecting therapies in relapsed and refractory multiple myeloma. Throughout the discussion, the speakers highlight how the updated guidelines support clinicians in navigating an increasingly complex therapeutic landscape. Guests: Prof. Meletios Dimopoulos and Prof. Evangelos Terpos National and Kapodistrian University of Athens, Greece Host: Prof. Pieter Sonneveld Erasmus University Medical Center, Rotterdam, The Netherlands Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Where Are We Now With Immunotherapy in Multiple Myeloma? | 22 juin 2026 | 00:22:33 | |
Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities. Guests: Dr Paula Rodríguez-Otero Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Menin Inhibitors to Treat Acute Myeloid Leukemia (AML) | 01 juin 2026 | 00:19:42 | |
Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation. In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition, identify which AML patient populations are most likely to benefit, and review the current clinical evidence supporting their use in defined molecular subtypes. Guests: Dr Scott Armstrong Dana-Farber Cancer Institute Prof Marc Raaijmakers Erasmus Medical Center Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How Experts Treat HIV-associated Lymphomas | 13 mai 2026 | 00:11:20 | |
Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas. In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments. This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL, Burkitt lymphoma, plasmatic lymphoma, and more. Finally, Prof Hubel advocates for the inclusion of people living with HIV in lymphoma clinical trials to increase evidence base on HIV-associated lymphomas and improve the care for this specific patient populations. Link to the guideline: Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - Hübel - 2024 - HemaSphere - Wiley Online Library Guest: Prof Kai Hübel Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Hematology Portraits: Associate Prof Meritxell Alberich Jordà | 07 mai 2026 | 00:18:30 | |
Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia.
Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding about leading a lab. Tune in to hear what she wishes she’d known at the very beginning of her journey. Guest: Associate Prof Meritxell Alberich Jordà Institute of Molecular Genetics of the Czech Academy of Sciences, Laboratory of Haematooncology Head, Prague, Czech Republic The Childhood Leukaemia Investigation Prague in the Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How Experts Treat Large B-cell Lymphoma (LBCL) | 23 avr. 2026 | 00:18:18 | |
Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library). Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines, walk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up. Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our guests explain treatment strategies for first-line and relapse/refractory patient populations, highlighting the practice-changing introduction of CAR T therapy in second-line for eligible patients. Finally, they discuss the disparities of access to innovative treatments across Europe and explore future perspectives of LBCL management in Europe and beyond. Guests: Prof Catherine Thieblemont and Prof Marie José Kersten. Professor Catherine Thieblemont from Saint-Louis Hospital in Paris. Professor Marie José Kersten from Amsterdam University Medical Centers (UMC) Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Connecting Hematology Research and Real Life: Peter Kapitein | 10 avr. 2026 | 00:25:04 | |
In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies. Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How Experts Treat Peripheral T- and NK-cell Lymphomas | 03 avr. 2026 | 00:29:33 | |
Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy). In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell lymphomas. Our guests explain the conscious effort of the guidelines panel to provide evidence based detailed recommendations for each subtype of PTCLs to improve diagnosis, treatment, and follow up. The emphasis is on moving away from “one size fits all” DLBCL style approach toward entity- adapted strategies. Throughout the conversation, they stress the need to read the full guideline – including the supplementary material – and the importance of a multidisciplinary approach by experienced hematopathologists, ideally in expert or reference centres to give patients the best chance of appropriate, modern therapy. GuestS: Prof Francesco D'Amore and Prof Massimo Federico. Professor Francesco D'Amore is a Clinical Professor and Chair of the Department of Hematology at Aarhus University in Denmark Professor Massimo Federico is a Senior Professor of Medical Oncology at the University of Modena and Reggio Emilia in Italy Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Hematology Portraits: Prof Konstanze Döhner | 16 mars 2026 | 00:17:11 | |
Join EHA President Prof Konstanze Döhner from University Hospital Ulm in Germany as she discusses her deep interest in hematology, both in research and in the clinics. Listen as Prof. Döhner shares why she decided to focus on Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPNs) in her career as a medical doctor, a researcher and a educator. Tune in to hear Prof. Döhner describe her journey to becoming the EHA president and her reflections on the current challenges in the hematology field and the solutions she proposes to address those. Guest: Prof Konstanze Döhner, University Hospital Ulm, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How Blood Cells Age: From Stem Cells to Clones (with Dr Michael Milsom) | 27 févr. 2026 | 00:26:53 | |
In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic andimmune aging that does not focus solely on HSCs. He describes how inflammation‑driven stem cell activation and proliferation cause functional attrition and clonalselection of HSCs, contributing to clonal hematopoiesis. Learn about the mechanisms of blood cells aging andpotential interventions to slow down the process. Guest: Dr Michael Milsom Head of the Division of Experimental Hematology at the German Cancer Research Center, (DKFZ), and group leader at the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‑STEM), Heidelberg, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How Experts Treat Mantle Cell Lymphoma (with Prof Mats Jerkeman) | 06 févr. 2026 | 00:15:44 | |
Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) with Prof Mats Jerkeman (Lund University, Sweden). In this episode, he explains how biological risk factors, particularly TP53 mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including the expanding role of BTK inhibitors (such as ibrutinib) in first-line regimens. He further discusses the management relapsed/refractory MCL, where BTK inhibitors and CAR T-cell therapy have largely supplanted but not fully replaced allogeneic transplantation. Throughout the conversation, Prof Jerkeman emphasizes the dynamic evolution of MCL treatment and the need for ongoing guideline updates as new evidence emerges.
Link to the guideline: (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) Link to Lund University: Mats Jerkeman - Lund University Learn More Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus. What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Life After CAR T-cell Therapy: Jonathan Clark’s Journey with Mantle Cell Lymphoma and the Future of Patient Advocacy | 30 janv. 2026 | 00:12:27 | |
[This is a Rerelease. Episode first published on July 19, 2024.]Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma. Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission. Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions.
Host: Dr Sarah de Vlieger Guest: Jonathan Clark This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024. Learn More Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus. What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| The Role of Artificial Intelligence in Hematology (featuring Dr Gregor Hormann) | 23 janv. 2026 | 00:16:20 | |
[This is a Rerelease. Episode first published on November 22, 2024.]Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here. Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction. The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't." Host: Dr Wilson Lim Guest: Dr Gregor Hormann Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| How Does Climate Change Affect Hematology Practice? (with Dr Stephen Hibbs) | 16 janv. 2026 | 00:12:57 | |
[This is a Rerelease. Episode first published on November 1, 2024.] Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future. The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint. Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions.
Host: Dr Sarah de Vlieger Guest: Dr Stephen Hibbs Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Accelerating Clinical Trials with AI (with Dr Jan Moritz Middeke) | 13 janv. 2026 | 00:16:44 | |
[This is a Rerelease. Episode first published on April 11, 2025.] Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design. Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies. If you want to know more: https://www.nature.com/articles/s41746-024-01076-x Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr. Jan Moritz Middeke Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| EHA Junior Research Grant: Dr Ana Río-Machín’s Journey in AML Research and Collaborative Science | 12 déc. 2025 | 00:18:33 | |
Join us for this interview with Dr Río-Machín from Autonomous University of Madrid in Spain as she discusses her research on rare subtypes of acute myeloid leukemia (AML), which she conducted thanks to the EHA Junior Research Grant. Her discovery of transcriptional activator of key leukemia drivers in one of these subtypes may pave way to new therapeutic approaches. Tune in to hear dr. Río-Machín‘s call for more collaborative research to achieve impactful results for patients in the future. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr Ana Río-Machín Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Hematologists’ Role in the Management of Gaucher Disease (Prof Argiris Symeonidis and Prof Sam Salek) | 08 déc. 2025 | 00:26:46 | |
Join us for this discussion between Prof Argiris Symeonidis from University of Patras in Greece and Prof Sam Salek from University of Hertfordshire in UK who focus on the role of the hematologist in the diagnosis and management of patients with Gaucher disease. Prof Symeonidis and Prof Salek are both experts in recognizing and treating this rare lysosomal storage disorder and share their recommendations for hematologists to ensure earlier detection of this disease. Host: Prof. Sam Salek, University of Hertfordshire, UK Guest: Prof. Argiris Symeonidis, University of Patras, Rion, Greece Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Navigating the Toughest Challenges in Hematology Nursing: Insights from HNHCP Leaders | 28 nov. 2025 | 00:19:06 | |
Join us for this inspiring interview with Erik Aerts from University Hospital Zurich in Switzerland and Mairéad Ní Chonghaile from St. James’s Hospital in Ireland who discuss their extensive work within the Hematology Nurses & Healthcare Professionals Group (HNHCP). Erik, the President, and Mairéad, the Vice-President of HNHCP, describe their unwavering commitment to providing hematology education to nurses and other healthcare professionals to ensure the best possible care for their patients. Tune in to hear what their thoughts are on the future of nursing in hematology and how they envisage addressing its biggest challenges. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guests: Erik Aerts, Nurse Manager, University Hospital Zurich, Switzerland and President of Hematology Nurses & Healthcare Professionals Group (HNHCP) Mairéad Ní Chonghaile, Bone Marrow Transplant Coordinator, St. James’s Hospital, Dublin, Ireland and Vice-President of HNHCP Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| A Multiple Myeloma and MRD Pioneer: EHA 2025 Lifetime Achievement Award (Prof Jesús San-Miguel) | 21 nov. 2025 | 00:26:39 | |
Join us for this inspiring interview with prof. Jesús San-Miguel from Clínica Universidad de Navarra in Spain who discusses his extensive work to improve care for patients with multiple myeloma. Prof San-Miguel’s research and clinical contributions have shaped the current treatment landscape for multiple myeloma. For his contributions, he has received the 2025 EHA Lifetime Achievement Award. Tune in to hear his thoughts about the future of multiple myeloma management and the crucial role that collaborative research will play in it. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Jesús San-Miguel, Clínica Universidad de Navarra, Spain What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Young Hematologists in the Spotlight: EHA2025 Young EHA Award (Dr Mandy Lauw) | 14 nov. 2025 | 00:22:17 | |
Join us for this interview with Dr Mandy Lauw from Erasmus Medical Center in Rotterdam, Netherlands who describes her work to increase the visibility and voice of young hematologists within the EHA. For her unwavering efforts to improve the support and opportunities for young hematologists at the beginning of their career, Dr Lauw has been awarded the Young EHA Award. Tune in to hear about the many educational and mentoring programs EHA has available for young hematologists. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr Mandy Lauw Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Supporting Hematology Innovation: Outcomes of an EHA Junior Research Grant (with Dr Ferran Nadeu Prat) | 07 nov. 2025 | 00:19:23 | |
Join us for this interview with Dr Ferran Nadeu Prat from August Pi i Sunyer Biomedical Research Institute in Barcelona, Spain who discusses his work on evolution of chronic lymphocytic leukemia (CLL), which he conducted thanks to the EHA Junior Research Grant. Dr Nadeu Prat explains how the new insights into CLL evolution toward Richter transformation, which is a lethal complication of CLL, may lead to new therapeutic approaches. Tune in to hear his views on the future of this field and the role of collaborative research in achieving these goals. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr Ferran Nadeu Prat, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Ethical Considerations in Gene Therapy for Sickle Cell Disease and Thalassemia (with Prof Mariane de Montalembert) | 31 oct. 2025 | 00:24:35 | |
Join us for this conversation with prof. Mariane de Montalembert from Necker-Enfants Malades Hospital in France who discusses the current standards of care for patients with sickle cell disease and thalassemia, both in Europe and in sub-Saharan Africa. Prof. de Montalembert highlights the inequalities and the unique challenges in implementation of complex innovative treatments, such as gene therapy. Tune in to hear her thoughts on the possible solutions for these challenges and future directions in this field. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Mariane de Montalembert, Necker-Enfants Malades Hospital, Paris, France Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Point-of-care Tests for Neonatal Screening of Sickle Cell Disease (with Prof Béatrice Gulbis) | 24 oct. 2025 | 00:24:15 | |
Join us for this inspiring interview with prof Béatrice Gulbis from The Brussels University Hospital in Belgium who discusses her extensive work on implementing neonatal screening for sickle cell disease (SCD) in low-resource countries in Africa. Prof Gulbis has been involved in collaborative projects to implement the testing methods that best fit the specific contexts. Tune in to hear her recommendations for the optimal SCD screening systems and her hopes for the worldwide collaborative approach to improve care for patients with SCD. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Béatrice Gulbis, The Brussels University Hospital, Belgium What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| What the EHA Burnout Survey Reveals for Hematologists (with Dr. Côme Bommier) | 17 oct. 2025 | 00:18:41 | |
Join us for this interview with dr. Côme Bommier from Saint-Louis Hospital in Paris, France who describes the results of the recent EHA survey on burnout symptoms among hematology professionals in Europe. Dr. Bommier discusses the findings of the survey in the context of modifiable systemic factors. Tune in to hear him urge organizational reforms to ensure better work environments for hematologists, leading ultimately to better outcomes for patients. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr. Côme Bommier, Saint-Louis Hospital, Paris, France What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| EHA2025 Diversity, Equity, and Inclusion Award: Prof Anna Schuh | 10 oct. 2025 | 00:30:36 | |
Join us for this inspiring conversation with prof. Anna Schuh from University of Oxford in the United Kingdom who describes her efforts to improve access to care for patients with hematological diseases in East African countries. Prof. Schuh describes the experience of sharing her time between the UK and East Africa and how this has impacted her clinical practice in both environments. Tune in to hear what her views are on how the Global North and Global South can learn from each other to improve care for patients everywhere. Host: Wilson Lim, PhD, Medical Writer Guest: Prof Anna Schuh, University of Oxford, United Kingdom Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| A Successful Mentor’s Mindset: EHA2025 Education & Mentoring Award (Prof Jan Cools) | 03 oct. 2025 | 00:23:22 | |
Join us for this inspirational interview with prof. Jan Cools from KU Leuven in Belgium who received the EHA 2025 Education & Mentoring Award. Prof. Cools describes his approach to mentoring students and scientists, emphasizing the aspects that he finds most crucial in this role. Tune in to hear his thoughts about the future of mentoring, the place artificial intelligence may take in it and the importance of failure on the road to success. Host: Isabel Olivera-Martinez, PhD, Medical Writer, EHA Guest: Prof. Jan Cools, KU Leuven Department of Human Genetics, Belgium Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| EHA Clinical Excellence Award 2025: Prof Khaled Musallam | 26 sept. 2025 | 00:25:29 | |
In this episode, we sit down with prof. Khaled Musallam from Burjeel Medical City in United Arab Emirates who discusses his extensive work to improve care for patients with thalassemia. Prof. Musallam’s research and clinical contributions have reshaped the management of both non-transfusion-dependent thalassemia (NTDT) and transfusion-dependent thalassemia (TDT). Tune in to hear his views on the current practice and future directions in the prevention and treatment of morbidities associated with thalassemia. For a comprehensive review of all aspects of thalassemia, the EHA Thalassemia Program is available to all EHA Members on Campus. Stay tuned for future episodes! Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Khaled Musallam Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Setting the Standard for Quality Care in Hematologic Malignancies (with Prof John Gribben) | 17 sept. 2025 | 00:18:54 | |
Join us for this discussion between Robin Doeswijk, EHA European Affairs and prof. John Gribben from Barts Cancer Institute in the United Kingdom on the topic of equity in care of patients with hematologic malignancies. This discussion follows the recently published “European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological Malignancies”. Tune in to hear how this combination of organizational guidelines and clinical practice recommendations aims to improve diagnosis and care for all patients across Europe. Host: Robin Doeswijk, EHA European Affairs Guest: Prof John Gribben Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Hematology Portraits: Prof Kirsten Grønbæk | 29 août 2025 | 00:21:45 | |
Join us for this captivating interview with Prof Kirsten Grønbæk from University of Copenhagen in Denmark, as she discusses her outstanding career in the field of hematology, both in research and in the clinics. Listen to how the interests of Prof Grønbæk evolved, leading her from the initial focus on epigenetics in lymphomas to MDS in the later years of her career. Prof Grønbæk reflects on the current developments in MDS and her tips for the leading a successful research team in hematology. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Kirsten Grønbæk Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Hematology Portraits: Prof Maria Domenica Cappellini | 22 août 2025 | 00:27:18 | |
In this episode, we sit down with Prof. Maria Domenica Cappellini from the University of Milan in Italy, as she discusses her inspiring career as a hematologist specializing in the management of patients with thalassemia. Listen to the compelling story of how Prof. Cappellini’s interest in thalassemia started and how her relentless stride for the best possible care for her patients has helped to transform the way this disease is managed. Tune in to hear prof. Cappellini’s words of advice for the younger generation of hematologists interested in the field of thalassemia. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Maria Domenica Cappellini Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Gene Therapy Advances in SCD and B-Thalassemia (with Dr Stefano Rivella) | 15 août 2025 | 00:39:39 | |
Explore the latest breakthroughs in gene therapy for sickle cell disease and beta thalassemia with Dr. Stefano Rivella, hematologist and research faculty at Children's Hospital of Philadelphia. In this episode, Dr. Rivella discusses the science behind FDA-approved therapies, compares gene addition and gene editing approaches, and shares insights on clinical safety, efficacy, and future innovations like in vivo gene therapy. Learn about the challenges of access, cost, and global equity, and discover how evolving technologies could transform treatment for patients worldwide. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr Stefano Rivella Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| AML Management in the Old and Unfit (with Prof Hartmut Döhner) | 08 août 2025 | 00:18:22 | |
Join us for this insightful interview with prof. Hartmut Döhner from University Hospital Ulm in Germany who tells about most recent developments in the management of older and unfit patients with AML. Prof. Döhner discusses all key aspects of the management including assessing patient fitness, genetic risk classification, and the choice of treatment, among which also the emerging therapies. Tune in, to hear about the most relevant recommendations for the clinical decision making while treating older unfit patients with AML. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Hartmut Döhner, University Hospital Ulm, Germany Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||
| Managing Young Fit AML patients with Prof Konstanze Döhner | 31 juil. 2025 | 00:13:06 | |
Join EHA President prof. Konstanze Döhner from University Hospital Ulm in Germany who discusses the most recent developments in the management of young and fit patients with AML. Tune in to hear about the diagnostic workup, risk stratification, treatment and the evolving role of measurable residual disease (MRD) measurements in clinical decision making in this group of patients. Prof. Döhner also shares her thoughts on the future of the treatment landscape for AML. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Konstanze Döhner Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe | |||